Clinical Trial Update: Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly [Phase 2]

View source ↗

Summary

Phase II trial evaluating immunogenicity and safety of fractional intradermal doses versus full intramuscular doses of inactivated poliovirus vaccine (IPV) for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• IPOL (inactivated poliovirus vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Poliomyelitis | Phase 2 | Status: COMPLETED